Abstract Background and objectives: To determine the effects of intravenous immunoglobulin (IVIg) on the course of late hyporegenerative anemia and the requirement for exchange transfusions, phototherapy and top-up red blood cell transfusions due to rhesus hemolytic disease of the newborn (Rh-HDN). Patients and methods: This is retrospective cohort study of newborns with Rh-HDN who were treated with or without IVIg. Relevant maternal and neonatal data were obtained and analyzed. All infants were followed up as outpatients for a period of 2e3 months, and during the follow ups, complete blood counts (RBCs) were performed every two weeks to diagnose late hyporegenerative anemia. Results: Sixty-six infants with Rh-HDN were enrolled in this study (42 in the IVIg group and 24 in the no-IVIg group). We observed no significant differences between the two groups in terms of maternal age, number of previous children affected with Rh-HDN, intrauterine transfusions, gestational age (GA), birth weight (BW), Apgar scores at the 1st or 5th minutes, exchange transfusions, or days on phototherapy. The serum bilirubin immediately after birth and the maximum serum bilirubin during the hospital course were significantly higher in the IVIG group (P Z 0.0035 and P Z 0.0225, respectively). Although there were no statistically significant differences, there was a trend toward the late anemia in the IVIg group being diagnosed and resolved earlier than in the no-IVIg group. Additionally, a greater proportion of the IVIg group required three or more top-up transfusions compared to the no-IVIg group, but this difference was not statistically significant. Conclusion: IVIg might have had an effect on the early development of late anemia and might have shortened the duration of late anemia relative to the infants who did not receive IVIg. The exchange transfusions and the days on phototherapy were not affected by IVIg.
Introduction
The cause of late hyporegenerative anemia is not well understood; however, several mechanisms have been suggested, including intramedullary destruction of red blood cell (RBC) precursors by RBC antibodies, bone marrow suppression from IUTs, and erythropoietin production that is inappropriately low for the degree of anemia [1e4] . The perinatal effects of maternal Rh alloimmunization are now referred to as hemolytic disease of the fetus and newborn (Rh-HDN), and these effects are considered the most common cause of severe hemolytic disease of the newborn. Prevention can be achieved by administering anti-D immunoglobulin G prophylaxis soon after delivery to prevent sensitization in Rh-negative women. Intrauterine transfusion is a method that is used to treat anemia in the fetus and results in decreases in mortality and the occurrence of fetal hydrops.
Hyporegenerative anemia is a well-known complication of Rh-HDN with an incidence that ranges from 71 to 83%. This condition typically presents at 1e3 weeks of age and can last up to 3 months [5e7]. Hyporegenerative anemia usually resolves spontaneously but causes significant morbidity due to the prolonged need for RBC transfusions.
In addition to the use of phototherapy and exchange or top-up transfusion therapies for jaundiced neonates, IVIg has been shown to decrease the rate of exchange transfusions in severely affected infants [8e11]. In contrast, a randomized, double-blind, placebo-controlled trial that included 92 newborn found no difference in the rate of exchange transfusions between an IVIg group and a placebo group [12] . Additionally, there were no significant differences between the groups with respect to the need for exchange transfusions, phototherapy time, peak bilirubin, or length of hospital stay.
Erythropoietin has been tried as a treatment for late hyporegenerative anemia, and the results have been promising. Reports have shown that recombinant human erythropoietin (rHuEPO) is effective in treating or preventing late hyporegenerative anemia (Refs. [13, 14] ).
In this retrospective cohort study, we aimed to determine the effects of intravenous immunoglobulin (IVIg) on the course of late hyporegenerative anemia and the requirements for exchange transfusions, days of phototherapy and top-up RBC transfusions secondary to Rh-HDN.
Patients and methods
All infants admitted to the NICU with Rh-HDN from January 2005 to December 2010 were identified using the NICU logbook and the NICU database. Rhesus HDN was defined by a maternal antibody-dependent cell-mediated cytotoxicity assay result exceeding 50% and a validated functional test predicting severe hemolysis comparable to an indirect antiglobulin titer of >1:64 [15] . Late anemia was defined as a hemoglobin level below the threshold requiring a top-up transfusion during the first three months of life. Top-up transfusions were given to anemic infants during their early hospital course due to hemolysis, and top-up transfusions were given to infants who developed late hyporegenerative anemia during the follow up.
The relevant neonatal and maternal data that were collected from the medical records of the infants and their mothers included the following: maternal age, affected previous children, intrauterine blood transfusion, infant demographic data (i.e., age, birth weight, sex and Apgar score), hemoglobin levels during the hospital course, bilirubin levels, use of phototherapy, top-up and exchange transfusions, age at the diagnosis of late hyporegenerative anemia and the resolved and number of top-up transfusions. All infants were followed up as outpatients for a period of 2e3 months. During the follow up, complete blood counts were performed for all infants every two weeks to diagnose late hyporegenerative anemia. The infants were classified into two groups as follows: group 1 was composed of infants who received IVIg, and group 2 was composed of infants who did not receive IVIg. Infants with major congenital anomalies were excluded from this study.
Statistical methods
In this study, all statistical analyses were performed with the software package SAS version 9.3 (Statistical Analysis System, SAS Institute Inc., Cary, NC, USA). Descriptive statistics for the continuous variables are reported as the means AE the standard deviations, and categorical variables are summarized as the frequencies and percentages. The continuous variables for the two groups of patients were compared with Student's independent t-tests, and the categorical variables were compared with chi-square tests and Fisher's exact tests. The statistical level of significance was set at p < 0.05.
Results
Sixty-six infants with Rh-HDN were enrolled in this study. Forty-two infants (IVIg group; 22 males) received IVIg at 0.5e1 g/kg, which was administered over 4 h and repeated every 12 h as necessary. The other 24 infants (no-IVIg group; 13 males) did not receive IVIg and served as a control for the IVIg group. As shown in Tables 1 and 2 , there were no significant differences between the two groups in maternal age, number of previous children affected with Rh-HDN, intrauterine transfusions, GA, BW, Apgar scores at the 1st or 5th minutes, hemoglobin immediately after birth (114.7 AE 41.6 vs. 130 AE 46, P Z 0.1476), reticulocyte count (0.9410 AE 1.0571 vs. 0.5933 AE 0.6140, P Z 0.6048), number of top-up transfusions (1.3 AE 0.5 vs.1.3 AE 0.5, P Z 0.8740), number of exchange transfusions (1.4 AE 0.5 vs.1.8 AE 1.3, P Z 0.4913), days on phototherapy (3.9 AE 2.1 vs. 3.4 AE 1.9, P Z 0.2373), hemoglobin level at the first diagnosis of late anemia (75.3 AE 11vs. 77 AE 25, P Z 0.7293), age (in days) at the diagnosis of late anemia (34.9 AE 13.9 vs. 43.2 AE 19.8, P Z 0.0665), age (in days) at the resolution of late anemia (46.5 AE 13.9 vs. 65.5 AE 2, P Z 0.1098), or the number of top-up transfusions for late hyporegenerative anemia (1.8 AE 1.0 vs. 1.8 AE 0.7, P Z 0.8472). The serum bilirubin immediately after birth and the peak serum bilirubin during the hospital course were significantly higher in the IVIg group (P Z 0.0035 and P Z 0.0225) respectively. Although there were no statistically significant differences, the late anemia in the IVIg group exhibited a trend toward being diagnosed and resolved earlier than in the no-IVIg group. Additionally, a greater proportion of the IVIg group required 3 or more top-up transfusions (n Z 6) compared to the noIVIg group (n Z 2), but this difference was not statistically significant (P Z 0.2776).
Discussion
In this retrospective chart review of two cohorts of newborns with Rh-HDN who were treated with or without IVIg, we found that late hyporegenerative anemia in the IVIg group was diagnosed and resolved earlier compared to the no-IVIg group. Additionally, a greater proportion of the IVIg group required three or more top-up transfusions (n Z 6) compared to the no-IVIg group (n Z 2), but this difference was not statistically significant. This latter result might have been mediated by the down regulating effect of IVIg on erythropoietin. One study showed that IVIg increases the production of proinflammatory cytokines, which in turn reduces erythropoietin production [16] . Another study showed that neonates with anti-glycophorin C hemolytic disease of fetuses and newborns are unresponsive to erythropoietin and that this lack of responsiveness can explained by the antibody inhibiting a protein kinase through which this hematopoietic growth factor achieves its effects [17] .
Moreover, our study showed that the serum bilirubin levels immediately after birth and the peak serum bilirubin levels during the hospital course were higher in the IVIg group; these findings indicate that the disease was severe in the IVIg group, which necessitated the use of IVIg was used. The study also showed that the numbers of exchange transfusions and days on phototherapy did not statistically differ between the two groups. These findings are in accordance with the results of several studies. In a randomized doubleblind trial, Santos MC et al. [12] found no difference in the All numerical variables are expressed as the means AE the SDs, and the categorical variables are expressed as the numbers of infants. LA Z late anemia, *P < 0.05 was considered significant.
frequencies of exchange transfusions between IVIg and placebo groups (6 of 46 (13%) in the IVIg group versus 7 of 46 (15.2%) in the placebo group (p Z 0.765)). Additionally, there were no significant differences between these groups with respect to their need for exchange transfusion, phototherapy time, peak bilirubin, or length of hospital stay. In another randomized, double-blind, placebo-controlled trial of neonates with rhesus hemolytic disease, Smits-Wintjens and colleagues [18] found no differences in the frequencies of exchange transfusions between IVIg and placebo groups, in the number of exchange transfusions per patient, or in the duration of phototherapy. In contrast, Elalfy and colleagues [19] studied 90 full-term neonates with Rh incompatibility who were randomly assigned into one of three groups: group I was treated with conventional methods; and groups IIa and IIb received IVIg once at 12 h postnatally if phototherapy was indicated in doses of 0.5 and 1 g/kg, respectively. These authors found that IVIg administration at 12 h was effective in the treatment of severe Rh-HDN. The low-dose of IVIg (0.5 g/ kg) was found to be as effective as the high-dose (1 g/kg) in reducing the duration of phototherapy and the hospital stay but was effective in avoiding exchange transfusion. In a systematic review of six randomized and quasi-randomized controlled trials that compared HDIVIG and phototherapy with phototherapy alone in neonates with Rh and/or ABO incompatibility, the authors found that significantly fewer infants required exchange transfusions in the HDIVIG group. Additionally, these authors found that the hospital stay and duration of phototherapy were significantly reduced [9] . Moreover, Girish and colleagues [20] compared the effects of two dose regimes of IVIg (0.5 g/kg vs. 1 g/kg given soon after birth) on the duration of phototherapy in Rh-isoimmunized neonates at !32 week gestation and found that the two regimes produced comparable effect on the duration of phototherapy, the duration of the hospital stay and the requirements for exchange transfusions. A Cochrane review (Ref. [21] ) in 2002 that included 189 term and preterm infants and infants with rhesus and ABO incompatibility concluded that the use of exchange transfusion was significantly decreased in the immunoglobulintreated group and that the mean number of exchange transfusions per infant was also significantly lower in the immunoglobulin-treated group. Although the results revealed a significant reduction in the need for exchange transfusion in those who were treated with intravenous immunoglobulin, the authors stated that the applicability of the results is limited; these authors suggested that results from additional trials of higher quality should be awaited. In 2004, The American Academy of Pediatrics (AAP) recommended the use of IVIg (0.5e1.0 g/kg) for rhesus HDN in cases in which phototherapy failed on the basis of the same limited data [22] .
A systematic review of randomized and quasirandomized controlled trials comparing high-dose intravenous immunoglobulin and phototherapy to phototherapy alone in infants with HDN due to Rh and/or ABO incompatibility has been reported. Six randomized trials were identified, but only four were included in the review (a total of 226 infants). Three studies reported the numbers of exchange transfusions and the fourth exchange and red cell transfusions together. Meta-analysis of the results of the four trials revealed a significant reduction in the need for exchange transfusions (relative risk (RR) 0.28, 95% confidence intervals (CI) 0.17e0.47). The number needed to treat was 2.7 [9] . One recent systematic review evaluated the efficacy and safety of IVIg in neonates with isoimmune hemolytic disease. Twelve studies, including 10 trials (n Z 463) of Rh isoimmunization and five trials (n Z 350) of ABO isoimmunization (three studies included both populations), were included. The studies with high risks of bias showed that IVIg reduced the rate of ET in Rh isoimmunization, whereas the studies with low risks of bias that used prophylactic phototherapy did not show a statistically significant difference. In contrast, the metaanalysis of the studies with high risks of bias in neonates with ABO isoimmunization revealed the efficacy of IVIg in reducing exchange transfusions [23] . The limitations of our study are primarily the small sample size and the use of medical charts as the source of information.
Conclusion
Although there were no statistically significant differences between the two groups, there were trends that indicated that IVIg might have exerted effects on the early development of late anemia and shortened the duration of late anemia relative to the infants who did not receive IVIg. The numbers of exchange transfusions and the days on phototherapy were not affected by IVIg. To avoid these limitations, confirm the results and uncover more or less favorable results, we recommend that a large prospective cohort study that includes other local institutions that manage infants with HDN due to Rh and/or ABO incompatibility should be conducted.
